Pneumonia is a type of lung infection caused by microorganisms such
as bacteria, virus, fungi and parasites. Streptococcus pneumonia is
one of the most common causes of pneumonia among children, others are
Haemophilus influenzae type b (Hob) and Pneumocystis jiroveci. It is
characterized by symptoms such as short breathing, fever, chest pain,
nausea and vomiting. In pneumonia the air sacs of lungs called as
alveoli are filled with fluid or pus that causes inflammation. The
treatment of pneumonia depends on severity of symptom and types of
pathogens. Usually, antibiotics are given to treat pneumonia caused
by bacterial infection while to treat pneumonia caused by fungi,
antifungals are prescribed.
It is quite difficult to diagnose pneumonia as its clinical symptoms
overlap with many other diseases such as the asthama, bronchitis and
common cold. In order to confirm pneumonia, a doctor recommends tests
including chest X-ray, blood tests, sputum test, CT scan, pleural
fluid culture and pulse oximetry test. The market for pneumonia
diagnostics and technologies can be estimated on the basis of volume
of tests generated at hospitals, diagnostic laboratories, physician’s
own clinics and other healthcare settings. Chest x-ray and CT scan
are generally recommended at hospitals for the diagnosis of pneumonia
while community healthcare settings usually recommend diagnosis on
the basis of symptoms. Some of the key players operating in this
market space are Becton Dickinson, Affymetrix, Bio-Rad, Abbott
Laboratories, Roche, Thermo Fisher Scientific, bioMeriux, DiaSorin
and Novartis Diagnostics. Some of the diagnostic kits available in
the market are Directigen S. pneumonia test kit by Becton Dickinson
and LCx Chlamydia pneumonia PCR assay kit by Abbott Laboratories.
Pneumonia Diagnostics & Technologies Market:
http://bit.ly/2eErhX2
The market for pneumonia diagnostics and technologies is projected to
grow under the influence of increasing aging population, recent
advances in pneumonia diagnostics and high prevalence of pneumonia
among children. Rapid increase in aging population in North America,
Europe and Japan will be driving the market in these regions as elder
people are more susceptible to develop pneumonia compared to general
population. As of April 2013, WHO (world health organization)
suggests that pneumonia is one of the major factors causing death in
children. It is estimated that every year approximately 1.2 million
children under the age of five years die due to pneumonia. This
disease is most prevalent in South Asia and African countries. The
recent advancement in pneumonia diagnostics such as the development
of nucleic acid detection tests for major pneumonia pathogens and
immunochromatographic pneumococcal urinary antigen tests are
predicted to drive the market globally.
No comments:
Post a Comment